Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: Influence of the ACE insertion/deletion polymorphism

Pharmacogenetics and Genomics

Volumn 19, Issue 9, 2009, Pages 695-703

  Vegter, Stefan ^a,b   Perna, Annalisa ^d   Hiddema, Wĝtse ^a   Ruggenenti, Piero ^d,e   Remuzzi, Giuseppe ^d,e   Navis, Gerjan ^a,b   Postma, Maarten J ^a,c  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b Division of Nephrology   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^e OSPEDALI RIUNITI   (Italy)

Author keywords

Angiotensin converting enzyme inhibitors; Chronic kidney failure; Cost effectiveness analysis; End stage renal disease; Genetic polymorphism

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; RAMIPRIL;

ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FOLLOW UP; GENOTYPE; HUMAN; INDEL MUTATION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RENAL PROTECTION; RENAL REPLACEMENT THERAPY; SENSITIVITY ANALYSIS; SURVIVAL TIME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COST-BENEFIT ANALYSIS; HUMANS; KIDNEY FAILURE, CHRONIC; MARKOV CHAINS; MUTAGENESIS, INSERTIONAL; PEPTIDYL-DIPEPTIDASE A; PLACEBO EFFECT; POLYMORPHISM, GENETIC; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RENAL DIALYSIS; SEQUENCE DELETION;

EID: 70249147235     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283307ca0     Document Type: Article

References (35)

1. Van Dijk PC, Jager KJ, Stengel B, Gronhagen-Riska C, Feest TG, Briggs JD. Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000). Kidney Int 2005; 67:1489-1499. Dutch End-Stage Renal Disease Registry (RENINE). 2009
2. Dale PL, Hutton J, Elgazzar H. Utility of health states in chronic kidney disease: a structured review of the literature. Curr Med Res Opin 2008; 24:193-206
3. Peeters P, Rublee D, Just PM, Joseph A. Analysis and interpretation of cost data in dialysis: review of Western European literature. Health Policy 2000; 54:209-227
4. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349:1857-1863
5. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351:1941-1951
6. Heeg JE, de Jong PE, van der Hem GK, de ZD. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989; 36:272-279
7. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86:1343-1346
8. Ruggenenti P, Bettinaglio P, Pinares F, Remuzzi G. Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies. Clin J Am Soc Nephrol 2008; 3:1511-1525
9. Ruggenenti P, Perna A, Zoccali C, Gherardi G, Benini R, Testa A, et al. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen). J Am Soc Nephrol 2000; 11:88-96 (Pubitemid 30020430)
10. Perna A, Ruggenenti P, Testa A, Spoto B, Benini R, Misefari V, et al. ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies1. Kidney Int 2000; 57:274-281
11. Vegter S, Boersma C, Rozenbaum M, Wilffert B, Navis G, Postma MJ. Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines. Pharmacoeconomics 2008; 26:569-587
12. Flowers CR, Veenstra D. The role of cost-effectiveness analysis in the era of pharmacogenomics. Pharmacoeconomics 2004; 22:481-493
13. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15:361-387
14. Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 2005; 365:939-946
15. Haas M, Yilmaz N, Schmidt A, Neyer U, Arneitz K, Stummvoll HK, et al. Angiotensin-converting enzyme gene polymorphism determines the antiproteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease. Austrian Study Group of the Effects of Enalapril Treatment in Proteinuric Renal Disease. Kidney Blood Press Res 1998; 21:66-69
16. Van der Kleij FG, Schmidt A, Navis GJ, Haas M, Yilmaz N, de Jong PE, et al. Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE inhibition: role of sodium status. Kidney Int Suppl 1997; 63:S23-S26
17. Van der Kleij FG, Navis GJ, Gansevoort RT, Heeg JE, Scheffer H, de ZD, et al. ACE polymorphism does not determine short-term renal response to ACE-inhibition in proteinuric patients. Nephrol Dial Transplant 1997; 12 (Suppl 2):42-46
18. Van Essen GG, Rensma PL, de ZD, Sluiter WJ, Scheffer H, Apperloo AJ, et al. Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy. Lancet 1996; 347:94-95
19. Yoshida H, Mitarai T, Kawamura T, Kitajima T, Miyazaki Y, Nagasawa R, et al. Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest 1995; 96:2162-2169
20. Gorodetskaya I, Zenios S, McCulloch CE, Bostrom A, Hsu CY, Bindman AB, et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int 2005; 68:2801-2808
21. Gold M, Siegel J, Russell L. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996
22. De Wit GA, Ramsteijn PG, de Charro FT. Economic evaluation of end stage renal disease treatment. Health Policy 1998; 44:215-232. Dutch drug prices [in Dutch]. Available at: http://www.medicijnkosten.nl. Accessed August 2008
23. Costa-Scharplatz M, van Asselt AD, Bachmann LM, Kessels AG, Severens JL. Cost-effectiveness of pharmacogenetic testing to predict treatment response to angiotensin-converting enzyme inhibitor. Pharmacogenet Genomics 2007; 17:359-368
24. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press 2005
25. Brouwer WB, Niessen LW, Postma MJ, Rutten FF. Need for differential discounting of costs and health effects in cost effectiveness analyses. BMJ 2005; 331:446-448
26. Oostenbrink JB, Bouwmans CA, Koopmanschap MA, Rutten FF. Guideline for costing research, methods and standardized prices for economic evaluations in health care. Diemen, The Netherlands: Health Care Insurance Board; 2004
27. Berger ML, Bingefors K, Hedblom EC, Pashos CL, Torrance GW. Health care costs, quality, and outcomes - ISPOR book of terms
28. Lawrenceville, NJ: International Society of Pharmacoeconomics and Outcomes Research (ISPOR); 2003
29. Foundation for Statistical Computing. R: A language and environment for statistical computing. 2007. Vienna, Austria. Ref Type: Computer Program
30. Van Hout BA, Simen GP, McDonnell J, Mann JF. Economic evaluation of benazepril in chronic renal insufficiency. Kidney Int Suppl 1997; 63:S159-S162
31. Ruggenenti P, Pagano E, Tammuzzo L, Benini R, Garattini L, Remuzzi G. Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney Int 2001; 59:286-294
32. Schädlich PK, Brecht JG, Brunetti M, Pagano E, Rangoonwala B, Huppertz E. Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance. Pharmacoeconomics 2001; 19:497-512
33. Lely AT, van der Kleij FG, Kistemaker TJ, Apperloo AJ, de Jong PE, de ZD, et al. Impact of the preintervention rate of renal function decline on outcome of renoprotective intervention. Clin J Am Soc Nephrol 2008; 3:54-60
34. Van der Sman-de Beer F, Verhagen C, Rombach SM, Boorsma P, van Manen JG, Korevaar JC, et al. ACE I/D polymorphism is associated with mortality in a cohort study of patients starting with dialysis. Kidney Int 2005; 68:2237-2243
35. Brenchley PE, Lindholm B, Dekker FW, Navis G. Translating knowledge of the human genome into clinical practice in nephrology dialysis and transplantation: the renal genome network (ReGeNet). Nephrol Dial Transplant 2006; 21:2681-2683